Assertio (ASRT) Competitors

Terns Pharmaceuticals (NASDAQ:TERN) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Does the MarketBeat Community believe in TERN or ASRT?

Assertio received 69 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 59.68% of users gave Assertio an outperform vote while only 59.15% of users gave Terns Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Terns Pharmaceuticals	Outperform Votes 42 59.15%	Underperform Votes 29 40.85%
Assertio	Outperform Votes 111 59.68%	Underperform Votes 75 40.32%

Do analysts rate TERN or ASRT?

Terns Pharmaceuticals currently has a consensus target price of $18.30, suggesting a potential upside of 446.27%. Assertio has a consensus target price of $2.75, suggesting a potential upside of 281.94%. Given Terns Pharmaceuticals' higher possible upside, equities research analysts plainly believe Terns Pharmaceuticals is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Assertio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in TERN or ASRT?

98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has stronger earnings & valuation, TERN or ASRT?

Terns Pharmaceuticals has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.18	-2.84
Assertio	$124.96M	0.55	-$331.94M	-$0.23	-3.13

Is TERN or ASRT more profitable?

Terns Pharmaceuticals has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Terns Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Terns Pharmaceuticals	N/A	-32.76%	-31.33%
Assertio	-54.46%	3.79%	1.81%

Does the media prefer TERN or ASRT?

In the previous week, Assertio had 5 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 12 mentions for Assertio and 7 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.73 beat Assertio's score of -0.39 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Terns Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, TERN or ASRT?

Terns Pharmaceuticals has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Summary

Assertio beats Terns Pharmaceuticals on 10 of the 17 factors compared between the two stocks.